Efficacy and tolerability of pharmacotherapy for post-stroke depression: A network meta-analysis

Oncotarget

Volumn 9, Issue 34, 2018, Pages 23718-23728

  Deng, Linghui ^a   Qiu, Shi ^a   Yang, Yan ^a   Wang, Lu ^a   Li, Yuxiao ^a   Lin, Jing ^a   Wei, Qiang ^a   Yang, Lu ^a   Wang, Deren ^a   Liu, Ming ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Hamilton depression scale; Network meta analysis; Pharmacotherapy; Post stroke depression

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; REBOXETINE;

ADVERSE OUTCOME; ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; META ANALYSIS; OUTCOME ASSESSMENT; POST-STROKE DEPRESSION; TREMOR;

EID: 85046805110     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.23891     Document Type: Article

References (54)

1. Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and metaanalysis of observational studies. Int J Stroke. 2014; 9: 1017-1025
2. Morris PL, Robinson RG, Andrzejewski P, Samuels J, Price TR. Association of depression with 10-year post-stroke mortality. Am J Psychiatry. 1993; 150:124-129
3. Bartoli F, Lillia N, Lax A, Crocamo C, Mantero V, Carrà G, Agostoni E, Clerici M. Depression after stroke and risk of mortality: a systematic review and meta-analysis. Stroke Res Treat. 2013; 2013:862978
4. Turner-Stokes L, Hassan N. Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 1: Diagnosis, frequency and impact. Clin Rehabil. 2002; 16:231-247
5. Naess H, Lunde L, Brogger J, Waje-Andreassen U. Depression predicts unfavourable functional outcome and higher mortality in stroke patients: The Bergen Stroke Study. Acta Neurol Scand Suppl. 2010; 122:34-38
6. West R, Hill K, Hewison J, Knapp P, House A. Psychological disorders after stroke are an important influence on functional outcomes: a prospective cohort study. Stroke. 2010; 41:1723-1727
7. Wulsin L, Alwell K, Moomaw CJ, Lindsell CJ, Kleindorfer DO, Woo D, Flaherty ML, Khatri P, Adeoye O, Ferioli S, Broderick JP, Kissela BM. Comparison of two depression measures for predicting stroke outcomes. J Psychosom Res. 2012; 72:175-179
8. Carson AJ, MacHale S, Allen K, Lawrie SM, Dennis M, House A, Sharpe M. Depression after stroke and lesion location: a systematic review. Lancet. 2000; 356:122-126
9. Robinson RG, Jorge RE. Post-Stroke Depression: A Review. Am J Psychiatry. 2016; 173:221-231
10. Jørgensen TS, Wium-Andersen IK, Wium-Andersen MK, Jørgensen MB, Prescott E, Maartensson S, Kragh-Andersen P, Osler M. Incidence of Depression After Stroke, and Associated Risk Factors and Mortality Outcomes, in a Large Cohort of Danish Patients. JAMA Psychiatry. 2016; 73:1032-1040
11. Folstein MF, Maiberger R, McHugh PR. Mood disorder as a specific complication of stroke. J Neurol Neurosurg Psychiatry. 1977; 40:1018-1020
12. House A, Knapp P, Bamford J, Vail A. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke. 2001; 32:696-701
13. Cole MG, Elie LM, McCusker J, Bellavance F, Mansour A. Feasibility and effectiveness of treatments for post-stroke depression in elderly inpatients: systematic review. J Geriatr Psychiatry Neurol. 2001; 14:37-41
14. Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke. 2005; 36:1098-1103
15. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008; 4:CD003437
16. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Nortriptyline treatment of post-stroke depression: a doubleblind study. Lancet. 1984; 1:297-300
17. Reding MJ, Orto LA, Winter SW, Fortuna IM, Di Ponte P, McDowell FH. Antidepressant therapy after stroke. A double-blind trial. Arch Neurol. 1986; 43:763-765
18. Chen Y, Guo JJ, Zhan S, Patel NC. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother. 2006; 40:2115-2122
19. Chollet F, Acket B, Raposo N, Albucher JF, Loubinoux I, Pariente J. Use of antidepressant medications to improve outcomes after stroke. Curr Neurol Neurosci Rep.2013; 13:318
20. Bryer JB, Starkstein SE, Votypka V, Parikh RM, Price TR, Robinson RG. Reduction of CSF monoamine metabolites in post-stroke depression: a preliminary report. J Neuropsychiatry Clin Neurosci. 1992; 4:440-442
21. Gerdelat-Mas A, Loubinoux I, Tombari D, Rascol O, Chollet F, Simonetta-Moreau M. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage. 2005; 27:314-322
22. Miyai I, Reding MJ. Effects of Antidepressants on Functional Recovery Following Stroke: A Double-Blind Study. J Neuro Rehab. 1998; 12:5-13
23. Lokk J, Delbari A. Management of depression in elderly stroke patients. Neuropsychiatr Dis Treat. 2010; 6:539-549
24. Carod-Artal FJ. Post-stroke depression (II): Its differential diagnosis, complications and treatment. Rev Neurol. 2006; 42:238-44
25. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol. 1999; 19:467-89
26. Dechant KL, Clissold SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991; 41:225-253
27. Bonnin A, Zhang L, Blakely RD, Levitt P. The SSRI citalopram affects fetal thalamic axon responsiveness to netrin-1 in vitro independently of SERT antagonism. Neuropsychopharmacology. 2012; 37:1879-1884
28. Lundmark J, Scheel Thomsen I, Fjord-Larsen T, Manniche PM, Mengel H, Møller-Nielsen EM, Pauser H, Wålinder J. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand Suppl. 1989; 350:76-80
29. Purgato M, Papola D, Gastaldon C, Trespidi C, Magni LR, Rizzo C, Furukawa TA, Watanabe N, Cipriani A, Barbui C. Paroxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2014; 4:CD006531
30. Sugarman MA, Loree AM, Baltes BB, Grekin ER, Kirsch I. The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales. PLoS One. 2014; 9:e106337
31. Horváth S, Karányi Z, Harcos P, Nagy Z, Németh G, Andor G. Clinical effectiveness and safety of paroxetine in post-stroke depression: results from a phase 4, open label, multicenter clinical trial with 26 weeks of follow-up. Orv Hetil. 2006; 147:2397-2404
32. Turner S, Hassan N. Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: Treatment alternatives. Clin Rehabil. 2002; 16:248-60
33. Karaiskos D, Tzavellas E, Spengos K, Vassilopoulou S, Paparrigopoulos T. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci. 2012; 24:349-353
34. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008; 23:161-169
35. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004; 311:576-584
36. Wang YM, Li N, Yang LL, Song M, Shi L, Chen WH, Li SX, Wang XY, Lu L. Randomized controlled trial of repetitive transcranial magnetic stimulation combined with paroxetine for the treatment of patients with first-episode major depressive disorder. Psychiatry Res. 2017; 254:18-23
37. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med. 2000; 132:738-42
38. Espárrago Llorca G, Castilla-Guerra L, Fernández Moreno MC, Ruiz Doblado S, Jiménez Hernández MD. Post-stroke depression: an update. Neurologia. 2015; 30:23-31
39. Mitchell PB. Selective serotonin reuptake inhibitors: adverse effects, toxicity and interactions. Adverse Drug React Toxicol Rev 1994; 13: 121-44
40. Yap KB, Low ST. Interaction of èuvoxamine with warfarin in an elderly woman. Singapore Med J 1999; 40: 480-82
41. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62
42. Williams JB. Standardizing the Hamilton Depression Rating Scale: past, present, and future. Eur Arch Psychiatry Clin Neurosci. 2001; 251:6-12
43. Worboys M. The Hamilton Rating Scale for Depression: The making of a ''gold standard'' and the unmaking of a chronic illness, 1960-1980. Chronic Illn. 2013; 9:202-219
44. Turner-Stokes L. Post-stroke depression: getting the full picture. Lancet. 2003; 361:1757-8
45. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002; 159:469-473
46. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162:777-84
47. Sun X, Deng L, Qiu S, Tu X, Wang D, Liu M. Pharmacological and psychotherapeutic interventions for management of post-stroke depression: A Bayesian network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017; 96:e6100
48. Higgins G, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. Updated March, 2011 London: The Cochrane Collaboration, 2011
49. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188
50. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008; 17:279-301
51. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network metaanalysis: concepts and models for multi-arm studies. Res Synth Methods. 2012; 3:98-110
52. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-analyses. BMJ. 2003; 327:557-60
53. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004; 23:3105-3124
54. Salanti G, Giovane CD, Chaimani A, Caldwell DM, Higgins JPT. Evaluating the quality of evidence from a network meta-analysis. PLoS One 2014; 9:e99682